- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| 07.08. | Evommune, Inc. GAAP EPS of -$0.89 | 1 | Seeking Alpha | ||
| 03.08. | Evommune Aktie: H.C. Wainwright bestätigt "Neutral"-Rating | 1 | Investing.com Deutsch | ||
| 03.08. | Evommune stock: H.C. Wainwright reiterates Neutral rating | 1 | Investing.com | ||
| 30.07. | Evommune doses first patient in migraine prevention trial | 1 | Investing.com | ||
| 30.07. | Evommune startet Phase-2b-Studie zur Migräneprophylaxe mit EVO756 | 1 | Investing.com Deutsch | ||
| 30.07. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.06. | EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal | 1 | Zacks | ||
| 30.06. | Evommune stock downgraded by H.C. Wainwright after trial failure | 2 | Investing.com | ||
| 29.06. | Studien-Fehlschlag schickt Evommune Aktie auf Talfahrt | 7 | Investing.com Deutsch | ||
| 29.06. | Evommune's Skin Disorder Study Falls Short | 3 | Benzinga.com | ||
| 29.06. | Raymond James stuft Evommune nach gescheiterter Studie herab | - | Investing.com Deutsch | ||
| 29.06. | Raymond James cuts Evommune stock rating on trial miss | 2 | Investing.com | ||
| 29.06. | William Blair stuft Evommune Aktie auf 'Market Perform' herab | 2 | Investing.com Deutsch | ||
| 29.06. | Evommune stock rating cut to Market Perform by William Blair | 1 | Investing.com | ||
| 29.06. | Evommune's phase 2b trial flops, ending challenge to Novartis in hives | 12 | FierceBiotech | ||
| 29.06. | Evommune drops on phase 2 data for EVO756 in urticaria | 3 | Seeking Alpha | ||
| 29.06. | Evommune's EVO756 fails phase 2b trial in chronic urticaria | 3 | Investing.com | ||
| 29.06. | Evommune, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 02.06. | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | H.C. Wainwright reiterates Evommune stock rating on trial progress | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,228 | +2,24 % | BioNxt erreicht wichtigen Meilenstein im klinischen Cladribin-Programm für MS mit Abschluss des IMPD vor Beginn der klinischen Studien am Menschen | VANCOUVER, BC / ACCESS Newswire /
26. August 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| CLINUVEL | 5,318 | -0,26 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,680 | +1,20 % | B.Riley stuft Cardiol Therapeutics mit Kauf ein: Kursziel impliziert über 400 % Potenzial | ||
| ATAIBECKLEY | 6,300 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,520 | -0,40 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,840 | +4,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| CYTODYN | 0,192 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,958 | -2,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 20,870 | +0,72 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CEL-SCI | 1,310 | +1,55 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,215 | 0,00 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| CURIS | 1,462 | +14,43 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,074 | 0,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,875 | +3,27 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen |
EVOMMUNE INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 13,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.